Skip to main content


Gilead's COVID-19 drug is mediocre. It will be a blockbuster anyway.

By The New York Times  
   October 29, 2020

Gilead Sciences said Wednesday that remdesivir, which has been authorized for emergency use since the spring, brought in $873 million in revenues so far this year.

Full story

Get the latest on healthcare leadership in your inbox.